Type 2 Diabetes Mellitus: Update Bulletin [April 2016]
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of Type 2 Diabetes Mellitus (T2DM). Topics covered include expert opinions on the positive data reported by Novo Nordisk for its novel GLP-1 analogue, semaglutide, from the Phase III SUSTAIN-1 and SUSTAIN-5 trials, the delivery device for semaglutide and the future opportunities for oral semaglutide in T2DM. Experts also discuss the positive cardiovascular safety data published for Victoza in the LEADER trial, and shed light on the recent US-FDA issued warnings about heart failure risk to the labels of T2DM medicines containing saxagliptin (Onglyza) and alogliptin (Nesina).
- How do KOLs view the positive data announced for Novo Nordisk’s once-weekly GLP-1 analogue, semaglutide, from the SUSTAIN-1 and SUSTAIN-5 Phase III trials?
- How do KOLs expect semaglutide to perform in an already crowded treatment landscape?
- Which once-weekly GLP-1 monotherapies are the preferred choice?
- In light of positive Phase II data, what do KOLs think about the oral formulation of semaglutide compared to injectable GLP-1s?
- Does GLP-1/SGLT2 combination therapy have a future as a first-line treatment for T2DM?
- How do KOLs perceive the positive cardiovascular safety data reported with Victoza in the LEADER study?
- What is the consensus among experts about the FDA-issued safety warnings and label alterations for medications containing saxagliptin (Onglyza) and alogliptin (Nesina)?
